AHA 2024 Key Takeaways: Innovations in Managing Heart Failure
Orly Vardeny, PharmD, MS, discusses how glucagon-like peptide-1 receptor agonists demonstrate multiple cardioprotective mechanisms including reduced inflammation, improved glucose metabolism, and enhanced endothelial function, while clinical trials of both finerenone and ferric carboxymaltose evaluate specific outcomes in patients with heart failure through rigorous study protocols.
Episodes
December 11th 2024EP. 1: Unraveling GLP-1 Agonists and Cardiovascular Protection
A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.
December 11th 2024EP. 2: Hyperkalemia and Heart Failure Insights
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
December 18th 2024EP. 3: Iron Deficiency and Cardiovascular Interventions
A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.
